Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Wednesday's Featured Story Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But Alexander Green, an Oxford Club strategist and bestselling author, says in his new book The American Dream that we're still in one of the best times in history to build wealth—especially if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Gold recently broke above $4,200 an ounce, and with analysts now calling for $6,000 under a Trump administration, seasoned investors are quietly moving part of their savings into physical gold before the next surge hits. With inflation lingering, the dollar weakening, and central banks hoarding at record levels, this may be one of the last chances to lock in today's prices and protect your retirement before volatility returns. Get your Free Wealth Preservation Guide while this window is still open Green attributes the dip to two core concerns. First, investors are beginning to question elevated valuations in tech and AI, especially as earnings season forces those expectations into the spotlight. Second, inflation readings and slower hiring have cooled hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" stance, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict next week's moves, Green encourages investors to zoom out. He calls himself "a long-term optimist" and points out that, historically, the market's trend has been up and to the right. For traders, caution may be warranted in the short term, but for long-term investors these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One of the most reliable indicators in times like these is insider buying. Green suggests that when officers and directors—people with access to non-public financial information—are putting money into their own companies, that's worth noting. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren't always right, their actions can serve as a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and lower costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL has developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has even used the test himself and calls it "a good feeling" to know you're clear of so many deadly diseases—especially ones like pancreatic cancer that often go undetected until late stages. With FDA fast-track status and potential insurance reimbursement ahead, Green sees GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Of course, biotech comes with risk. Most drugs never make it through all three phases of clinical trials. Still, large pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) are actively acquiring promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example. The company invested in a private prostate cancer drug before it received FDA approval—underscoring just how aggressive Big Pharma can be when clinical trials look promising. He believes biotech is especially compelling now because healthcare is largely recession-proof. Whether the economy is growing or contracting, people still seek treatment. For investors looking to weather volatility, sectors like healthcare, utilities, consumer staples, and food companies offer steady demand—and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the notion that it's out of reach and was surprised to see polls showing nearly 70% of Americans believe it's no longer attainable. The reality, he says, is that with access to low-cost investment tools, no-commission trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to follow through. He breaks it down simply: if a 25-year-old invests $190 a month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and leave that money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says it doesn't have to be. Mortgage rates have roughly doubled and prices are up about 50% since the pandemic—but there are still ways to get in. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method sometimes called a "contract for deed." It might not get you the perfect house immediately, but it can help you start building equity sooner than you think. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green's message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
